The offices in Boston and San Francisco will open in early 2015, the Shanghai, China-headquartered contract research organisation (CRO) announced today, increasing its presence in the US to seven locations.
“The locations are driven by access to the two leading biotech hubs in the world, Boston and San Francisco,” WuXi spokesman Ronald Aldridge told Outsourcing-Pharma.com.
While global communications means deals can be made without being in specific locations, Aldridge said “physical proximity is still important for person-to-person contact,” and was thus a key driver for these offices.
Ge Li, Chairman and CEO of WuXi added in a statement: “These new offices bring our comprehensive platform of integrated R&D services closer to where entrepreneurs are and where cutting-edge science is being done.”
In total, the CRO presently has 15 offices worldwide with ten located in China.